Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Shire plc (LSE: SHP and NASDAQ: SHPG) ("Shire"), Baxalta Incorporated, a Delaware corporation and wholly-owned subsidiary of Shire ("Baxalta"), and...
Shire plc (LSE: SHP, NASDAQ: SHPG) announces its third annual #FlyforMPS campaign to allow rare champions around the world to recognize and raise...
VEYVONDI is the first and only recombinant von Willebrand factor treatment for adults with von Willebrand disease, the most common inherited bleeding ...
Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved MYDAYIS[TM] (mixed salts of a...
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will participate at the Jefferies Healthcare...
New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives Shire plc...
Study met primary endpoint demonstrating significantly greater remission rates in patients receiving anti-MAdCAM antibody (SHP647) compared to...
Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration Data to serve as basis for U.S....
Shire plc (LSE: SHP, NASDAQ: SHPG) will present research on the evolving needs of adults living with Attention-Deficit/Hyperactivity Disorder (ADHD)...
Commercial execution, efficiency improvements, and debt pay-down remain top priorities Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) announces unaudited ...
Demonstrates ongoing commitment to innovation in ophthalmics for Shire P-321 is a Phase 2 investigational topical treatment for dry eye disease Shire ...
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission (EC) has granted Conditional Marketing Authorisation for Natpar...
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Deutsche Bank 42nd annual health...
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, is launching #PIPostsThanks, a social campaign to spotlight the unsung heroes ...
On World Hemophilia Day 2017, Shire challenges the community to collectively improve global standards of care for rare bleeding disorders Shire plc...
A New Non-stimulant Clinical Option for Children and Adolescents From 6 to 17 Years old With ADHD Shire plc (LSE: SHP, NASDAQ: SHPG) today announced...
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for...
CINRYZE is now the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics Shire plc (LSE: SHP, NASDAQ: SHPG)...
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases and highly specialized conditions, will present data assessing primary...
Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Jeff Poulton, Chief Financial Officer, will participate at the Cowen 37th Annual Healthcare...
This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the...
Results Served as Basis for Ongoing Phase 3 Trial Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced the...
- For Every 'Count', Shire Will Donate to Leading Rare Disease Organizations - Campaign Honoring Rare Disease Day Open to All at...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.